Benzinga | Oct 15, 2021 10:32AM EDT

Synlogic Presents Data On Hyperoxaluria Program At American Society Of Nephrology Kidney Week 2021

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 -- 7th, 2021.

The two posters will be available throughout the duration of the conference:

* Poster #3605649: Relationship Between 24-hr Urinary Oxalate and Incident Chronic Kidney Disease Among Patients with and without Underlying Gastrointestinal Disease In one of the largest longitudinal retrospective observational cohort studies of urinary oxalate to date, >750,000 individuals with at least one 24-hr urine collection were identified. The risk of incident chronic kidney disease increased with increasing 24-hour urine oxalate (UOx) excretion, with an odds ratio of 1.67 (95% CI: 1.51, 1.86) for the highest UOx group compared with the lowest UOx group.

* Poster #3605510: Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery As previously disclosed, the dose of 3e11 live cells was identified in healthy volunteers and demonstrated to be well-tolerated. At this dose, the percent reduction from baseline UOx levels was -28.6% (90% CI: -42.4 to -11.6) compared to placebo in diet-induced hyperoxaluria. Part B of the study is a double-blind, placebo-controlled crossover study of SYNB8802 in subjects with enteric hyperoxaluria and a history of Roux-en-Y gastric bypass surgery. Part B remains ongoing and results are expected in 2022.

Posters will be made available on the Synlogic website following the event.